Tag Archives: Harvard School of Public Health

Pharma Pricing Top Target for Medicare Cutbacks

By Jill Wechsler | Published: January 28, 2013
In the dog-eat-dog world of federal deficit reduction, there seems to be one health-related spending cut with broad bi-partisan support:  require drug companies to give the federal government “a better deal on medications for low-income people on Medicare.” Nearly 70% of respondents back this strategy, according to a survey sponsored by the Kaiser Family Foundation [...]
Posted in healthcare, pricing | Also tagged , , , , , , | 2 Comments

Pharma Celebrates its Own

By Andrew Sheivachman | Published: October 7, 2009
At the gala ceremony for the 2009 Prix Galien USA award on October 1, a paradigm shift in drug development took center stage. “The most successful new [cancer] therapies will be based on a precise molecular understanding of disease basis—that’s exactly what we did with Gleevec,” said keynote speaker Brian Druker, director of the Oregon Health [...]
Posted in Events | Also tagged , , , , , , , , , , , , | Leave a comment

Prix Galien Push for Private/Public Collaboration

By Andrew Sheivachman | Published: October 6, 2009
Preceding the presentation of the 2009 Prix Galien USA prizes, last Tuesday, a round table discussion was conducted at the American Museum of Natural History on the subject of how public and private collaboration can increase innovation and contribute to saving lives around the world. The talk included Leonard Bell of Alexion Pharmaceuticals, Barry Bloom [...]
Posted in Events | Also tagged , , , , , , , | Leave a comment